Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Roberta Coletti"'
Publikováno v:
BioData Mining, Vol 17, Iss 1, Pp 1-36 (2024)
Abstract Background High-dimensional omics data integration has emerged as a prominent avenue within the healthcare industry, presenting substantial potential to improve predictive models. However, the data integration process faces several challenge
Externí odkaz:
https://doaj.org/article/6782224d4d6e4c348559e330ec160841
Publikováno v:
Bioinformatics and Biology Insights, Vol 18 (2024)
Tumor heterogeneity is a challenge to designing effective and targeted therapies. Glioma-type identification depends on specific molecular and histological features, which are defined by the official World Health Organization (WHO) classification of
Externí odkaz:
https://doaj.org/article/00375086e0834851b949ad735cf90da5
Publikováno v:
BioData Mining, Vol 16, Iss 1, Pp 1-16 (2023)
Abstract Gliomas are primary malignant brain tumors with poor survival and high resistance to available treatments. Improving the molecular understanding of glioma and disclosing novel biomarkers of tumor development and progression could help to fin
Externí odkaz:
https://doaj.org/article/3b6416b332c6459483a70127fbe83c1e
Autor:
Mónica L. Mendonça, Roberta Coletti, Céline S. Gonçalves, Eduarda P. Martins, Bruno M. Costa, Susana Vinga, Marta B. Lopes
The understanding of glioma disease has been evolving drastically with the dedicated research into the genetic and molecular profiling of glioma tumour tissue. Molecular biomarkers have gained progressive and substantial importance in providing diagn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::513140f1bd5d489947e3d6eedcb45f1d
https://doi.org/10.1101/2023.02.19.529134
https://doi.org/10.1101/2023.02.19.529134
Publikováno v:
Cancers
Cancers; Volume 14; Issue 1; Pages: 135
Cancers, Vol 14, Iss 135, p 135 (2022)
Cancers; Volume 14; Issue 1; Pages: 135
Cancers, Vol 14, Iss 135, p 135 (2022)
Simple Summary Although ipilimumab has been approved for the treatment of many types of cancer, most prostate cancer patients seem to not respond well to the therapy. Here, we mathematically investigate the clinical relevance of ipilimumab, as mono-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fee4c229eb7694ee1580f83a10d62984
https://pubmed.ncbi.nlm.nih.gov/35008298
https://pubmed.ncbi.nlm.nih.gov/35008298
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-18 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-18 (2020)
Immunotherapy, by enhancing the endogenous anti-tumor immune responses, is showing promising results for the treatment of numerous cancers refractory to conventional therapies. However, its effectiveness for advanced castration-resistant prostate can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2cb85f215eefbd2bb4b2e040e29c74c
https://doi.org/10.1038/s41598-020-65590-0
https://doi.org/10.1038/s41598-020-65590-0
Publikováno v:
Journal of theoretical biology. 509
In this paper we analyze the potential effect of immunotherapies on castration-resistant form of human Prostate Cancer (PCa). In particular, we examine the potential effect of the dendritic vaccine sipuleucel-T, the only currently available immunothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::833d63ff71374fe28b094f474456c249
https://pubmed.ncbi.nlm.nih.gov/32980372
https://pubmed.ncbi.nlm.nih.gov/32980372